Global In-Vitro Colorectal Cancer Screening Tests Market Size, Trends, and Growth Opportunity, By Product (Biomarker Tests, Fecal Occult Blood Test, and CRC DNA Screening Tests), End-User (Diagnostics laboratories, Hospitals, Clinics, and Ambulatory Surgical Centers), Imaging Type (Ultrasound, MRI, Colonoscopy, Proctoscopy, CT Scan, PET Scan), Application (MarCarePlex, Cologic, PanCDx, and MeSorce CRC, Colox, miRDIGN) By Region and forecast till 2030.
Global In-Vitro Colorectal Cancer Screening Tests Market
The global In-Vitro Colorectal Cancer Screening Tests Market was valued at USD 945.91 million in 2022 and is slated to reach USD 1636.02 million by 2030 at a CAGR of 7.08 % from 2023-2030.
The use of in-vitro colorectal cancer screening tests is common to find the disease. The rectum or colon is where colorectal cancer develops. Depending on where it starts, it might also be called colon or rectal cancer. A growth on the inner layer of the colon or rectum is where the majority of colorectal tumors start. A colonoscopy is also one of the most accurate methods for detecting colon cancer.
Market Drivers
During the projection period, it is anticipated that technological developments in colorectal cancer screening will accelerate market expansion. To address market demands for less intrusive diagnostic procedures, the FDA has approved a fecal DNA test and a blood test to identify colorectal cancer. Additionally, advances in industrial genetics have increased the use of in-vitro colorectal cancer screening tests by using DNA sequencing at low cost and fast speed, leading to market expansion. So, this is anticipated to promote market expansion. The third most prevalent cancer in the world, colorectal cancer (CRC) affects 1.36 million people worldwide and accounts for 10% of all cancer cases. In the United States, colorectal cancer caused about 142,820 new cases and 50,830 deaths in 2013; in Europe, it caused about 447,000 new cases and 215,000 deaths in 2012. Around 400000 new cases of colorectal cancer were anticipated in China in 2012. As a result, more screening tests are being done, which will aid in patient recovery due to the rising number of cancer occurrences. This thereby accelerates market expansion.
Market Restraints
Due to high expenses and tight budgets, many hospitals in developing and undeveloped countries are unable to invest in colorectal cancer screening. However, due to the enormous demand for diagnostic imaging operations in these nations, hospitals that cannot afford to purchase new and cutting-edge screening equipment use other options. As a result, this factor inhibits market expansion.
Impact of COVID-19
Routine colorectal cancer screenings have been postponed or cancelled because of the emphasis on COVID-19 patients and the desire to lower the risk of exposure. There are now fewer patients able to access screening tests as a result of numerous hospitals and clinics being forced to scale back or shut down entirely. The demand for in-vitro colorectal cancer screening tests has suffered as a result of this. In contrast, the pandemic has raised awareness of the value of early disease identification and prevention, especially colorectal cancer. The market for in-vitro colorectal cancer screening tests may expand as a result of the rise in interest in self-screening tests that may be completed at home.
Recent Developments
The United States Food and Drug Administration (U.S. FDA) declared the approval of GI Genius, a machine learning-based artificial intelligence device, in 2021. It is made public to assist medical professionals in identifying lesions during a colonoscopy, such as polyps or possible tumors.
Market Segmentation
The global In-Vitro Colorectal Cancer Screening Tests Market is segmented By Product, Application, Imaging Type, and End-User. By Products such as Biomarker Tests, Fecal Occult Blood Tests, and CRC DNA Screening Tests. By End-User such as Diagnostics laboratories, Hospitals, Clinics, and Ambulatory Surgical Centers. By Imaging Types such as Ultrasound, MRI, Colonoscopy, Proctoscopy, CT Scan, and PET Scan. By Applications such as MarCarePlex, Cologic, PanCDx, and MeSorce CRC, Colox, birding.
Regional Analysis
The global In-Vitro Colorectal Cancer Screening Tests Market is segmented into five regions Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rising incidence rate and enhanced healthcare infrastructure in North America have made it the industry leader. A growing older population was one of the factors contributing to market expansion. Due to the rising prevalence of cancer in this region, the market in the Asia Pacific is expected to experience tremendous growth. Additionally, as the older population in this region grows and Asian nations change their lifestyles to spur market expansion, cancer is becoming a bigger worry.
Key Players
This report includes a list of numerous Key Players, namely Immunostics Inc (U.S.), Abbott (U.S.), Beckman Coulter, Inc (U.S.), Sysmex Corporation (Japan), Siemens Healthcare Private Limited (Japan), Clinical Genomics Technologies Pty, Ltd (U.S.), Epigenomics AG (Germany), Quest Diagnostics Incorporated (U.S.), Eiken Chemical Co, Ltd (Japan), Merck KGaA (Germany).
Market Taxonomy
By Product
• Fecal Occult Blood Test
• Guaiac FOB Stool Test
• Immuno-FOB Agglutination Test
• Lateral Flow Immuno-FOB Test
• Immuno-FOB ELISA Test
• Biomarker Tests
• Tumor M2-PK Stool Test
• Transferrin Assasys
• CRC DNA Screening Tests
• Methylated Gene Test
• Panel DNA Test
By Imaging Type
• Colonoscopy
• Proctoscopy
• CT Scan
• Ultrasound
• MRI
• PET Scan
By End-User
• Hospitals
• Clinics
• Diagnostics laboratories
• Ambulatory Surgical Centers
By Application
• MarCarePlex
• Cologic
• Colox
• miRDIGN
• PanCDx
• MeSorce CRC
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa.
Global In-Vitro Colorectal Cancer Screening Tests Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global In-Vitro Colorectal Cancer Screening Tests Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing Economic Downturn
4.2.6 Post Covid-19 World Supply and Demand Conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global In-Vitro Colorectal Cancer Screening Tests Market, By Product
5.1 Y-o-Y Growth Comparison, By Product
5.2 Global In-Vitro Colorectal Cancer Screening Tests Market Share Analysis, By Product
5.3 Global In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Product
5.3.1 Fecal Occult Blood Test
5.3.2 Guaiac FOB Stool Test
5.3.3 Immuno-FOB Agglutination Test
5.3.4 Lateral Flow Immuno-FOB Test
5.3.5 Immuno-FOB ELISA Test
5.3.6 Biomarker Tests
5.3.7 Tumor M2-PK Stool Test
5.3.8 Transferrin Assasys
5.3.9 CRC DNA Screening Tests
5.3.10 Methylated Gene Test
5.3.11 Panel DNA Test
6 Global In-Vitro Colorectal Cancer Screening Tests Market, By Imaging Type
6.1 Y-o-Y Growth Comparison, By Imaging Type
6.2 Global In-Vitro Colorectal Cancer Screening Tests Market Share Analysis, By Imaging Type
6.3 Global In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Imaging Type
6.3.1 Colonoscopy
6.3.2 Proctoscopy
6.3.3 CT Scan
6.3.4 Ultrasound
6.3.5 MRI
6.3.6 PET Scan
7 Global In-Vitro Colorectal Cancer Screening Tests Market, By End-User
7.1 Y-o-Y Growth Comparison, By End-User
7.2 Global In-Vitro Colorectal Cancer Screening Tests Market Share Analysis, By End-User
7.3 Global In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By End-User
7.3.1 Hospitals
7.3.2 Clinics
7.3.3 Diagnostics laboratories
7.3.4 Ambulatory Surgical Centers
8 Global In-Vitro Colorectal Cancer Screening Tests Market, By Application
8.1 Y-o-Y Growth Comparison, By Application
8.2 Global In-Vitro Colorectal Cancer Screening Tests Market Share Analysis, By Application
8.3 Global In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Application
8.3.1 MarCarePlex
8.3.2 Cologic
8.3.3 Colox
8.3.4 miRDIGN
8.3.5 PanCDx
8.3.6 MeSorce CRC
9 Global In-Vitro Colorectal Cancer Screening Tests Market, By Region
9.1 Global In-Vitro Colorectal Cancer Screening Tests Market Share Analysis, By Region
9.2 Global In-Vitro Colorectal Cancer Screening Tests Market Share Analysis, By Region
9.3 Global In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Region
10 North America In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 North America In-Vitro Colorectal Cancer Screening Tests Market Share Analysis, By Product
10.3 North America In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Imaging Type
10.4 North America In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By End-User
10.5 North America In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Application
10.6 North America In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Country
10.6.1 U.S.
10.6.2 Canada
10.6.3 Mexico
11 Europe In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Europe In-Vitro Colorectal Cancer Screening Tests Market Share Analysis, By Product
11.3 Europe In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Imaging Type
11.4 Europe In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By End-User
11.5 Europe In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Application
11.5 Europe In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Country
11.6.1 Germany
11.6.2 France
11.6.3 UK
11.6.4 Rest of Europe
12 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market Share Analysis, By Product
12.3 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Imaging Type
12.4 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By End-User
12.5 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Application
12.6 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Country
12.6.1 China
12.6.2 Japan
12.6.3 India
12.6.4 Rest of Asia Pacific
13 Latin America In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Latin America In-Vitro Colorectal Cancer Screening Tests Market Share Analysis, By Product
13.3 Latin America In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Imaging Type
13.4 Latin America In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By End-User
13.5 Latin America In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Application
13.6 Latin America In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, Country
13.6.1 Brazil
13.6.2Rest of Latin America
14 Middle East In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Middle East In-Vitro Colorectal Cancer Screening Tests Market Share Analysis, By Product
14.3 Middle East In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Imaging Type
14.4 Middle East In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By End-User
14.5 Middle East In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Application
14.6 Middle East In-Vitro Colorectal Cancer Screening Tests Market Size and Forecast, By Country
14.6.1 Saudi Arabia
14.6.2 UAE
14.6.3 Egypt
14.6.4 Kuwait
14.6.5 South Africa
15 Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16 Company Profiles
16.1 Immunostics Inc (U.S.)
16.1.1 Overview
16.1.2 Offerings
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 Abbott (U.S.)
16.2.1 Overview
16.2.2 Offerings
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3 Sysmex Corporation (Japan)
16.3.1 Overview
16.3.2 Offerings
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 Beckman Coulter, Inc (U.S.)
16.4.1 Overview
16.4.2 Offerings
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Siemens Healthcare Private Limited (Japan)
16.5.1 Overview
16.5.2 Offerings
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 Clinical Genomics Technologies Pty, Ltd (U.S.)
16.6.1 Overview
16.6.2 Offerings
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 Epigenomics AG (Germany)
16.7.1 Overview
16.7.2 Offerings
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies
16.8 Quest Diagnostics Incorporated (U.S.)
16.8.1 Overview
16.8.2 Offerings
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9 Eiken Chemical Co, Ltd (Japan)
16.9.1 Overview
16.9.2 Offerings
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies
16.10 Merck KGaA (Germany)
16.10.1 Overview
16.10.2 Offerings
16.10.3 Key Financials
16.10.4 Business Segment & Geographic Overview
16.10.5 Key Market Developments
16.10.6 Key Strategies
